BAM
SANA icon

Belpointe Asset Management’s Sana Biotechnology SANA Stock Holding History

Belpointe Asset Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,185
Closed -$8.63K – 3836
2022
Q4 		$8.63K Buy
+2,185
New +$10.7K ﹤0.01% 2699

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Belpointe Asset Management's SANA Position: Q1 2023 in Review

Belpointe Asset Management sold out of Sana Biotechnology (SANA) in Q1 2023, closing a stake of 2,185 shares — an estimated $8.63K sold.

Belpointe Asset Management first reported a position in SANA in Q4 2022 and held it in 1 quarter. The position peaked at $8.63K in Q4 2022. 120 funds tracked by Wall St. Rank hold SANA as of Q1 2023.

  • Belpointe Asset Management reported no remaining Sana Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,185 Sana Biotechnology shares in Q1 2023, an estimated $8.63K.
  • Belpointe Asset Management first reported a position in Sana Biotechnology in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Sana Biotechnology position peaked at $8.63K in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.